The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.
This post was originally published on this site
media.net, 8CUUP9999, DIRECT rubiconproject.com, 19398, DIRECT, 0bfd66d529a55807 rubiconproject.com, 19398, RESELLER, 0bfd66d529a55807 pubmatic.com, 157599, DIRECT, 5d62403b186f2ace pubmatic.com, 157599, RESELLER, 5d62403b186f2ace openx.com, 537100188, RESELLER, 6a698e2ec38604c6 google.com, pub-7439041255533808, RESELLER, f08c47fec0942fa0 districtm.io, 100600, DIRECT rubiconproject.com, 17054, RESELLER pubmatic.com, 156181, RESELLER spotxchange.com, 211156, RESELLER, 7842df1d2fe2db34 spotx.tv, 211156, RESELLER, 7842df1d2fe2db34